Intellia Therapeutics, Inc
Here’s whether Intellia Therapeutics, Inc (NTLA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); strong 1-year return of +26.8%. Concerns: below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-1.83% over 10 days). Currently 54.5% off its 52-week high. Score: +1/7.
NTLA is holding above its long-term 200-day MA ($12.42) but has slipped below the 50-day MA ($13.29), pointing to short-term weakness in an otherwise intact trend. An RSI of 67.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +26.8% compares to +20.5% for SPY (beat the market by 6.3%). The current 54.5% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.